Alnylam Pharmaceuticals (ALNY) Receivables (2009 - 2026)

Alnylam Pharmaceuticals has reported Receivables for 18 years, with the latest figure at $884.0 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables rose 111.46% year-over-year to $884.0 million; the trailing twelve-month figure through Mar 2026 stood at $884.0 million (up 111.46% YoY), and the FY2025 full-year result was $777.6 million, up 91.85% from the prior year.
• Receivables for Q1 2026 stood at $884.0 million, up from $777.6 million in the prior quarter.
• The five-year high for Receivables was $964.8 million in Q3 2025, with the low at $9.1 million in Q2 2022.
• Historically, Receivables has averaged $363.6 million across 5 years, with a median of $325.4 million in 2023.
• Annual changes were most pronounced in 2022 — Receivables slumped 98.3% — and 2023, when it jumped 2331.51%.
• Alnylam Pharmaceuticals' Receivables stood at $32.3 million in 2022, then surged by 913.5% to $327.8 million in 2023, then grew by 23.65% to $405.3 million in 2024, then soared by 91.85% to $777.6 million in 2025, then gained by 13.68% to $884.0 million in 2026.
• The last three Receivables figures came in at $884.0 million (Q1 2026), $777.6 million (Q4 2025), and $964.8 million (Q3 2025), per Business Quant data.